To test this, B16F10 and Lewis lung cancer (LLC) tumor‐bearing mouse models were treated with Sunitinib, CTLA‐4 mAb, Sunitinib plus CTLA‐4 mAb, and control, respectively. Here, CTLA4 is linked to neoplasm.